Printer Friendly

/C O R R E C T I O N -- CORTECH/

 In DV001, "Cortech Conversion Rights Expire," moved Friday, Feb. 5, the first graph, fourth line, should read "4.6 million units" rather than "46 million units" as originally issued. The corrected version follows.
 CORTECH CONVERSION RIGHTS EXPIRE
 DENVER, Feb. 5 /PRNewswire/ -- David K. Crossen, president and chief executive officer of Cortech Inc. (NASDAQ: CRTQ), announced today that the common stock conversion rights issued in conjunction with the 4.6 million units Cortech Inc. sold in its Nov. 24, 1992, initial public offering have expired. The conversion rights detached and have traded separately from the common stock since Jan. 8, 1993.
 In accordance with the terms outlined in the company's prospectus, the conversion rights expired because the average of the closing prices of Cortech's common stock units on NASDAQ prior to the separation date and the company's common stock after that date exceeded $12 per share, or 50 percent above the initial offering price of $8, for the past 40 consecutive trading days. The rights provided for the issuance of additional shares of Cortech common stock 18 months after the IPO if the stock failed to appreciate 50 percent during that period.
 "The inclusion of the conversion rights reflected the company's confidence that significant milestones could be reached within the time frame that the rights remained viable and that these achievements would be translated into an appropriate increase in valuation," said Crossen.
 The registered units were issued and sold by the company. The offering was managed by Montgomery Securities and Hambrecht & Quist Inc.
 Cortech Inc. is a Denver-based biopharmaceutical company focused on the design and development of two novel classes of drugs, bradykinin antagonists and neutrophil elastase inhibitors to treat a broad range of inflammatory disorders. The company began enrolling patients in its Phase II SIRS/sepsis clinical trial on Jan. 21, 1993, for its first lead compound, a bradykinin antagonist called Bradycor. In addition, Cortech is developing a proprietary potential treatment for allergies and autoimmune diseases. No assurance can be given at this time that the company's therapeutic approaches will lead to successful product launches and product revenues.
 Cortech common stock is listed as CRTQ on NASDAQ.
 -0- 2/8/93
 /CONTACT: David K. Crossen, president and CEO, or Timothy C. Rodell, M.D., senior VP, operations and product development, of Cortech, 303-650-1200/
 (CRTQ)


CO: Cortech Inc. ST: Colorado IN: MTC SU:

JL -- DV003 -- 4132 02/08/93 12:51 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 8, 1993
Words:401
Previous Article:A&M SPECIALISTS PERSONNEL ANNOUNCEMENT
Next Article:ZEOS 486DX2-66 DESKTOP SYSTEM WINS 'BEST VALUE' AWARD FROM PC COMPUTING
Topics:


Related Articles
IBM AND MULTI SOFT SIGN SOFTWARE MARKETING AGREEMENT
DCA ANNOUNCES SELECT COMM SERVER WITH PC ROUTER SUPPORT
CompuServe, Golden CommPass Team Up To Reach OS-2 Market
IBM Ships OS/390 2.7, Previews Future Releases.
CAI to Help Make OS/390 Secure for E-Commerce.
DDH Releases Mobile TS on PalmGear.com; First Palm Application With the Ability to Connect to Windows Terminal Servers.
A magical pair of 6x6 chemical squares.
PalmSource Joins the Khronos Group; PalmSource to Advance 3D Graphics Capabilities on Palm Powered Devices.
Compuware Delivers Enhanced Enterprise Test Data Management Solution; Compuware File-AID/CS 3.0 Offers Rich Data-Management Functionality With...
Patients With HIV-Associated Wasting Gain More Weight With Concentrated Form of Megestrol Acetate, Study Shows.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters